Lumida
/TYRA
⌘K
Tyra Biosciences Inc

Tyra Biosciences Inc

TYRA
$22.03USD-6.41%-1.51 today

MARKET CAP

1.3B

P/E (TTM)

FWD P/E

DAY RANGE

$22 – $24

52W RANGE

$12
$41

AI Summary

Stalk
Sell NowMedium

The stock is in a Stage 3 distribution with declining EMAs and failed rally attempts, indicating a bearish medium-term environment. Short-term price action shows rejection at dynamic resistance after an oversold bounce, favoring sell-side execution on any rallies into the EMA zone. The long-term trend remains down with price below a falling 200DMA, anchoring a structural bearish bias.

  • SURF302 program enters pivotal trials with initial data due Sep 2026
  • $353.9 M cash reserves fund R&D through H2 2028
  • Earnings yield at –1.7% highlights poor revenue-to-profit conversion
Full analysis →

Buying

7

institutions

Selling

6

institutions

New Positions

0

this quarter

Filing Period

Q1 2026

latest 13-F

13-F Holdings

InstitutionActionShares HeldValueChangeChg %Weight
JH

Janus Henderson Group Plc

Q1 2026

BUY7.78 M297.73 M+4.85 M+286.2%0.07%
FC

Farallon Capital Management LLC

Q1 2026

BUY3.58 M137.15 M+1.51 M+152.4%0.00%
BI

Blackrock, Inc.

Q2 2026

BUY3.03 M96.84 M+814.04 K+14.0%0.00%
WP

Woodline Partners LP

Q2 2026

SELL320.04 K10.22 M+-282.04 K-55.7%0.03%
CA

Citadel Advisors LLC

Q2 2026

BUY278.31 K8.89 M+230.51 K+385.6%0.00%
MM

Millennium Management LLC

Q2 2026

SELL202.67 K6.47 M+-58.91 K-35.4%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY178.26 K5.74 M+111.47 K+148.6%0.00%
FA

Fisher Asset Management, LLC

Q2 2026

BUY60.23 K1.92 M+31.43 K+74.4%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY29.85 K953.50 K+430.00-15.4%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

SELL0.000.00+-351.48 K-100.0%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

SELL0.000.00+-218.95 K-100.0%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

SELL0.000.00+-38.61 K-100.0%0.00%
EP

Eversept Partners, LP

Q2 2026

SELL0.000.00+-27.05 K-100.0%0.00%